Side effects are manageable and well-characterized
The scale may not show dramatic numbers, but the mirror tells a completely different story
Dysautonomia, and specifically Postural Orthostatic Tachycardia Syndrome (POTS), frequently co-occurs with Long COVID and ME/CFS
Clinical trials signify average weight loss of 15 to 20 percent of body weight, especially when combined with lifestyle tailoring, affirming it as one of the most efficient weight loss medications currently available in Griffin
Similar content being viewed by others Introduction Weight regain (WR) and insufficient weight loss (IWL) are significant challenges faced by 2025% of patients following bariatric surgery, often stemming from a combination of anatomical variations, genetic predispositions, hormonal imbalances, dietary noncompliance, and inadequate physical activity [1,2,3]